

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal


Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]

Final Stakeholder List

Provisional consultees	Provisional commentators (no right to submit or appeal)
	out in appeal,
Company	General
AstraZeneca (acalabrutinib)	All Wales Therapeutics and Toxicology Centre
Patient/carer groups	Allied Health Professionals Federation
African Caribbean Leukaemia Trust	Board of Community Health Councils in
Anthony Nolan	Wales
Black Health Agency for Equality	British National Formulary
Blood Cancer UK	Care Quality Commission
Cancer Black Care	Department of Health - Northern Ireland
Cancer Equality	Healthcare Improvement Scotland
Cancer52	Medicines and Healthcare products
• DKMS	Regulatory Agency
Helen Rollason Cancer Charity	National Association of Primary Care
Independent Cancer Patients Voice	National Pharmacy Association
Kevin Karawa Leukaemia Trust	NHS Confederation
Leukaemia Cancer Society	Scottish Medicines Consortium
Leukaemia Care	Welsh Government
Leukaemia UK	Welsh Health Specialised Services Committee
Lymphoma Action Magnetition	Committee
Macmillan Cancer Support Magning Contract	Possible comparator companies
Maggie's Centres Mario Curio	Accord-UK Ltd (bendamustine)
Marie Curie South Asian Health Foundation	Aspire Pharma (bortezomib)
South Asian Health Foundation Specialized Healthcare Alliance	Aurobindo Pharma (bortezomib)
Specialised Healthcare AllianceTenovus Cancer Care	Baxter Healthcare Ltd
WMUK	(cyclophosphamide, doxorubicin)
VIVIOR	Biotech Pharma (bortezomib)
Healthcare professional groups	Celltrion Healthcare UK Ltd (rituximab)
Association of Cancer Physicians	Dr Reddy's Laboratories UK Ltd
British Geriatrics Society	(bendamustine, bortezomib)
British Institute of Radiology	Hospira UK Ltd (cytarabine, vincristine)
British Oncology Pharmacy	Jazz Pharmaceuticals UK (cytarabine)
Association	Johnson & Johnson Ltd (bortezomib)
British Psychosocial Oncology Society	medac GmbH (bortezomib, doxorubicin)
British Society for Haematology	MSN Laboratories Europe (bortezomib)

Final stakeholder list for the evaluation of acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]

Issue date: September 2024



Provisional consultees Provisional commentators (no right to submit or appeal) British Society of Interventional Mylan (bortezomib) Radiology Pfizer Ltd (bortezomib, doxorubicin, **British Transplantation Society** rituximab) Cancer Research UK Roche Products Ltd (rituximab) NHS Blood and Transplant Sandoz Ltd (bortezomib, cyclophosphamide, rituximab) Royal College of General Practitioners Seacross Pharmaceuticals Ltd Royal College of Nursing (bendamustine, doxorubicin) Royal College of Pathologists Sun Pharma (bortezomib) Royal College of Physicians Thornton & Ross Ltd (bortezomib) Royal College of Radiologists Tillomed Laboratories Ltd (bortezomib) Royal Pharmaceutical Society Zentiva Pharma Ltd (bendamustine) Royal Society of Medicine Society of Radiographers Relevant research groups **UK Clinical Pharmacy Association** Cochrane Haematological Malignancies **UK Oncology Nursing Society** Group **United Kingdom Cutaneous** Cochrane UK Lymphoma Group Genomics England Institute of Cancer Research **Others** Leukaemia Busters Department of Health and Social Care Lymphoma Research Trust NHS England MRC Clinical Trials Unit National Institute for Health Research Associated Public Health groups Public Health Wales UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.


Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Final stakeholder list for the evaluation of acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]

Issue date: September 2024



Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.